Particle Therapy Market - By Type (Proton, Heavy Ion), By Product (Synchrotrons, Cyclotrons), By Services, By System (Multi-Room Systems, Single-Room Systems), By Cancer Type (Pediatric Cancer, Lung Cancer, Bladder, Breast Cancer) & Forecast, 2024 – 2032

Particle Therapy Market Size

Particle Therapy Market size accounted for USD 837.09 million in 2023 and is estimated to grow at over 8.8% CAGR between 2024 and 2032. Particle therapy offers a multitude of advantages that serve as powerful growth drivers for its widespread adoption. One of the foremost drivers is its precision in targeting cancerous tissues. This precise targeting minimizes damage to surrounding healthy tissues, thereby reducing adverse effects, and enhancing patient quality of life during and after treatment.
 

The remarkable efficacy of particle therapy, especially for certain types of tumours that are resistant to conventional treatments is anticipated to aid market growth. Moreover, increasing number of particle therapy centers around the world are expected to drive market growth.
 

Particle therapy, also known as particle beam therapy, is an advanced form of cancer treatment that utilizes charged particles, such as protons or heavy ions, to deliver precise and targeted radiation therapy to cancerous tissues.
 

COVID-19 Impact

The emergence of the COVID-19 pandemic had a negative impact on particle therapy market. The pandemic led to widespread healthcare resource reallocation towards managing COVID-19 cases, diverting attention and resources away from non-COVID medical procedures, including particle therapy treatments. This shift resulted in delays or cancellations of scheduled treatments, causing setbacks in patient care and treatment plans, thereby hampering market growth. Additionally, travel restrictions and lockdown measures imposed to curb the virus's spread impeded patient access to particle therapy centers. Many patients were unable to travel to treatment facilities due to mobility restrictions or concerns about virus exposure, leading to a decline in patient numbers seeking particle therapy treatments. Such factors hindered market growth.
 

Particle Therapy Market Trends

Growing global burden of cancer is expected to boost the market growth. For instance, according to the American Cancer Society report, in 2022, there were an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. alone. As cancer cases continue to increase worldwide, the demand for innovative and effective treatment alternatives has become increasingly urgent. Particle therapy, known for its remarkable precision in targeting cancer cells while minimizing harm to healthy tissue, emerges as a compelling solution. Furthermore, particle therapy's ability to deliver highly focused radiation directly to the tumour site enhances the potential for successful outcomes and reduced collateral damage, thereby escalate the global market growth.
 

Particle Therapy Market Restraint

The particle therapy industry encounters a significant restraint in the form of infrastructural challenges within healthcare facilities. While particle therapy holds immense promise in revolutionizing cancer treatment, its successful implementation requires specialized infrastructure that can accommodate the unique demands of this advanced therapy. Furthermore, particle therapy centers need to house complex and sizable equipment, including particle accelerators and beam delivery systems, which demand substantial space and sophisticated shielding to ensure safety for both patients and medical staff. Moreover, the installation and maintenance of these intricate systems necessitate a high level of technical expertise and resources. Thus, the financial burden of establishing particle therapy facilities, coupled with the need for ongoing investments in maintenance and upgrades may hamper overall market growth.
 

Particle Therapy Market Analysis

By type, the particle therapy market is classified into proton therapy and heavy ion therapy. The proton therapy segment accounted for 72.7% of the market share in 2022 and is projected to witness significant growth over the analysis timeframe. The effectiveness of proton therapy is notably strong when dealing with paediatric cancers and intricate tumours situated near vital organs. Its ability to spare healthy tissues from unnecessary radiation exposure is crucial in these cases, making it a preferred option when considering the long-term well-being of patients, especially children. Furthermore, investments in research and development have led to the development of more compact and cost-effective proton therapy systems, making it feasible for a broader range of healthcare facilities to offer this advanced treatment option. Such aforementioned factors are expected to accelerate market statistics.
 

Based on product & services, the particle therapy market is segmented into product and services. The product segment accounted for 76.8% of the market share in 2022. The product segment is bifurcated into synchrotrons, cyclotrons, and synchrocyclotrons. Synchrotrons contribute to the advancement of research and innovation in particle therapy. Their versatile design allows for the exploration of various particle types and energies, enabling the development of tailored treatment plans for different cancer types. The versatility of synchrotrons also facilitates the conduct of cutting-edge experiments to refine treatment techniques and maximize therapeutic outcomes. Furthermore, the growing collaboration between research institutions and healthcare facilities in harnessing synchrotrons for particle therapy research contributes to their expansion.
 

Based on system, the particle therapy market is segmented into multi-room systems and single-room systems. The multi-room systems segment is projected to witness significant growth of 8.9% over the analysis timeframe. Multi-room systems notably enhance patient throughput and operational efficiency, allowing healthcare providers to concurrently treat multiple patients within a single facility. This efficient approach effectively reduces treatment waiting times and optimizes the utilization of valuable resources, thereby driving market growth. Furthermore, growing product approvals, launches, and partnerships among the companies are anticipated to escalate market demand.
 

Based on cancer type, the particle therapy market is segmented into pediatric cancer, lung cancer, bladder cancer, brain & spinal cord cancer, head & neck cancer, breast cancer, gastrointestinal cancer, and other cancer types. The lung cancer segment accounted for 15.5% of the market share in 2022 and is projected to witness significant CAGR over the analysis timeframe. Increasing prevalence of lung cancer across the globe is expected to accelerate segmental growth. For instance, according to the GLOBOCAN study carries out by the International Agency for Research on Cancer, in 2020, lung cancer was the major cause holding for the largest number of approximately 1.8 million cancer associated deaths followed by colorectal accounting for 9.4%, liver for 8.3%, stomach for 7.7%, and female breast cancer for 6.9%. Thus, the mounting burden of cancer will surge the investment in cancer research, thereby fostering market size.
 

North America particle therapy market accounted for 46% market share in 2022 and is anticipated to grow at considerable growth rate during the forecast timeframe. A significant driver propelling the growth of the market in North America is the region's robust research and development landscape coupled with substantial investments in healthcare innovation. This conducive environment fosters the continuous evolution of particle therapy technologies, leading to advanced treatment modalities and refined techniques. Additionally, the presence of prominent research institutions and collaborations between academia and healthcare facilities accelerates the validation and adoption of particle therapy. Furthermore, North America's emphasis on precision medicine and patient-centric care aligns well with the precision and tailored approaches that particle therapy offers, thereby boosting regional market statistics.
 

Particle Therapy Market Share

Major business players operating in the particle therapy market include

• Danfysik A/S
• Hitachi, Ltd.
• IBA
• Mevion Medical Systems
• Optivus Proton Therapy, Inc.

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Particle Therapy Industry News:

• In September 2021, ProTom International, a leading provider of compact proton therapy technology, has entered into an agreement with the Behnke Group, a Texas-based healthcare consulting firm. This strategy enhanced ProTom's expansion of U.S. markets through connections with the Behnke Group's network in the industry.
   
• In April 2020, Mevion Medical Systems received a medical device license from Health Canada for MEVION S250i proton therapy system with HYPERSCAN Pencil Beam Scanning (PBS). This strategy helped the company to expand their customer base.
   

The particle therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Type

• Proton therapy
• Heavy ion therapy

By Product & Services  

• Product
  • Synchrotrons
  • Cyclotrons
  • Synchrocyclotrons
• Services

By System  

• Multi-room systems
• Single-room systems

By Cancer Type

• Pediatric cancer
• Lung cancer
• Bladder cancer
• Brain & spinal cord cancer
• Head & neck cancer
• Breast cancer
• Gastrointestinal cancer
• Other cancers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa